UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 3, 2021

ASHLAND GLOBAL HOLDINGS INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

333-211719 (Commission File Number) 81-2587835 (I.R.S. Employer Identification No.)

8145 Blazer Drive Wilmington, DE 19808

Registrant's telephone number, including area code (302) 995-3000

	e appropriate box below if the Form 8-K lowing provisions:	filing is intended to simultaneous	usly satisfy the filing obligation of the registrant under any
	Written communications pursuant to Re	ule 425 under the Securities Act	(17 CFR 230.425)
	Soliciting material pursuant to Rule 14	a-12 under the Exchange Act (17	CFR 240.14a-12)
	Pre-commencement communications p	ursuant to Rule 14d-2(b) under the	ne Exchange Act (17 CFR 240.14d-2(b))
	Pre-commencement communications p	ursuant to Rule 13e-4(c) under the	ne Exchange Act (17 CFR 240.13e-4(c))
	by check mark whether the registrant is a or Rule 12b-2 of the Securities Exchange		defined in Rule 405 of the Securities Act of 1933 (17 CFR 2).
Emerging	growth company \square		
	rging growth company, indicate by chec new or revised financial accounting stand	<u>c</u>	ted not to use the extended transition period for complying on $13(a)$ of the Exchange Act. \square
Securities	registered pursuant to Section 12(b) of	the Act:	
Common S	Title of each class Stock (par value \$.01)	Trading Symbol(s) ASH	Name of each exchange on which registered NYSE

Item 2.02. Results of Operations and Financial Condition

On February 3, 2021, Ashland Global Holdings Inc. ("Ashland") announced preliminary first quarter results, which are discussed in more detail in the news release (the "News Release") attached to this Current Report on Form 8-K ("Form 8-K") as Exhibit 99.1, which is incorporated herein by reference into this Item 2.02.

Item 7.01. Regulation FD Disclosure

On February 3, 2021, Ashland will make available the News Release on the "Investor Center" section of Ashland's website located at http://investor.ashland.com.

Item 9.01. Financial Statements and Exhibits

- (d) Exhibits
- 99.1 News Release dated February 3, 2021.
- 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document).

In connection with the disclosures set forth in Items 2.02 and 7.01 above, the information in this Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section. The information in this Form 8-K, including the exhibit, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing. This Form 8-K will not be deemed an admission as to the materiality of any information in this Form 8-K that is required to be disclosed solely by Regulation FD.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ASHLAND GLOBAL HOLDINGS INC. (Registrant)

February 3, 2021

/s/ J. Kevin Willis

J. Kevin Willis Senior Vice President and Chief Financial Officer



News Release

Ashland reports preliminary financial results for first quarter of fiscal year 2021

- Sales of \$552 million, up four percent from the prior-year quarter
- Net income of \$56 million, or \$0.91 per diluted share
- Income from continuing operations of \$61 million, or \$0.99 per diluted share
- Adjusted income from continuing operations excluding intangibles amortization expense of \$58 million, or \$0.94 per diluted share
- Adjusted EBITDA of \$124 million
- Cash flows provided by operating activities of \$106 million; free cash flows of \$76 million

WILMINGTON, Del., February 3, 2021 – Ashland Global Holdings Inc. (NYSE: ASH) today announced preliminary¹ financial results for the first quarter of fiscal year 2021, which ended December 31, 2020. The global specialty materials company serves customers in a wide range of consumer and industrial markets.

Ashland's financial results during the quarter reflected execution of the company's strategy, solid overall demand and the benefit of continued cost reduction. The result was improved sales and earnings, margin growth and strong free cash flow generation. Sales were approximately \$552 million, up four percent compared to the prior-year period, as growth was realized in all three of Ashland's business groups.

Net income was \$56 million compared to net income of \$32 million in the prior-year quarter. Income from continuing operations was \$61 million compared to income of \$34 million in the prior-year quarter, or \$0.99 per diluted share compared to \$0.56 in the prior-year quarter. Adjusted income from continuing operations excluding intangibles amortization expense was \$58 million compared to \$25 million in the prior-year quarter, or \$0.94 per diluted share, up from \$0.41 in the prior-year quarter. Adjusted EBITDA was \$124 million, up from \$88 million in the prior-year quarter, driven primarily by lower operating expenses, favorable mix, improved sales in all three business groups and lower selling, general, administrative and research and development ("SARD") expenses.

Cash flows provided by operating activities totaled \$106 million compared to a deficit of \$34 million in the prior-year quarter. Free cash flows totaled \$76 million compared to a deficit of \$63 million in the prior-year quarter, driven primarily by increased earnings and disciplined working capital management.

"Ashland's financial results in the first quarter reflect our progress toward demonstrating strategic discipline, consistent organic growth, margin expansion and improved free cash flow conversion," said Guillermo Novo, chairman and chief executive officer, Ashland. "Our industrial businesses continue to see strong demand recovery, and excluding specific mix actions, our core consumer businesses continue to demonstrate top-line resilience and growth. All business groups expanded margins compared to the prior-year period. Also, Ashland's free cash flow improved dramatically when compared to the prior year, reflecting the broad-based efforts by our teams to grow earnings and continue to improve working capital."

"I am pleased with the progress our team has made driving more consistent performance while delivering profitable growth and improved cash generation," continued Novo. "While the

uncertainty related to the COVID-19 pandemic continues to impact global supply chains and consumer behavior, the continued progress made by our teams in the first-fiscal quarter gives me even more confidence in our ability to deliver consistent results. I look forward to sharing additional thoughts on our plans and the progress we have made during our earnings call tomorrow morning."

Reportable Segment Performance

To aid in the understanding of Ashland's ongoing business performance, the results of Ashland's reportable segments are described below on an adjusted basis. In addition, EBITDA and adjusted EBITDA are reconciled to operating income in Table 4. Free cash flow and adjusted operating income are reconciled in Table 6 and adjusted income from continuing operations, adjusted diluted earnings per share and adjusted diluted earnings per share excluding intangible amortization expense are reconciled in Table 7 of this news release. These adjusted results are considered non-GAAP financial measures. For a full description of the non-GAAP financial measures used, see the "Use of Non-GAAP Measures" section that further describes these adjustments below.

Consumer Specialties

Sales were \$296 million, up one percent from the prior-year quarter. Foreign currency favorably impacted sales by two percent. Strong demand in most consumer end markets was nearly offset by our exit from lower-margin product lines and continued Avoca challenges, both within Personal Care and Household.

Operating income was \$44 million, compared to \$33 million in the prior-year quarter. Adjusted EBITDA was \$79 million, up 18% from the prior-year quarter, reflecting favorable mix and lower SARD expenses in both the Life Sciences and Personal Care and Household segments.

Industrial Specialties

Sales were \$231 million, up eight percent from the prior-year quarter, driven by improving global demand for architectural coatings, construction and adhesive applications. Foreign currency favorably impacted sales by two percent.

Operating income was \$22 million, compared to \$19 million in the prior-year quarter. Adjusted EBITDA was \$55 million, up 28% from the prior-year quarter, driven by favorable volumes, mix and SARD expenses.

Intermediates & Solvents

Sales were \$33 million, up 18% from the prior-year quarter, primarily reflecting normalized internal sales volumes versus prior year when there was a planned extended shutdown at the Lima, Ohio facility.

Operating income was \$2 million, up from an operating loss of \$12 million in the prior-year quarter. Adjusted EBITDA was \$5 million, up from negative \$9 million in the prior-year quarter, which included the impact of the shutdown at the Lima facility.

Unallocated & Other

Unallocated and Other expense was \$27 million, compared to \$23 million in the prior-year quarter, primarily due to higher restructuring-related expenses. Adjusted Unallocated and Other expense was \$15 million, compared to an expense of \$16 million in the prior-year quarter.

Conference Call Webcast

Ashland will host a live webcast of its first-quarter conference call with securities analysts at 9:00 a.m. ET Thursday, February 4, 2021. The webcast will be accessible through Ashland's website at http://investor.ashland.com and will include a slide presentation. Following the live event, an archived version of the webcast and supporting materials will be available for 12 months.

Use of Non-GAAP Measures

Ashland believes that by removing the impact of depreciation and amortization and excluding certain non-cash charges, amounts spent on interest and taxes and certain other charges that are highly variable from year to year, EBITDA, adjusted EBITDA, EBITDA margin and adjusted EBITDA margin provide Ashland's investors with performance measures that reflect the impact to operations from trends in changes in sales, margin and operating expenses, providing a perspective not immediately apparent from net income, operating income, net income margin and operating income margin. The adjustments Ashland makes to derive the non-GAAP measures of EBITDA, adjusted EBITDA, EBITDA margin and adjusted EBITDA margin exclude items which may cause short-term fluctuations in net income and operating income and which Ashland does not consider to be the fundamental attributes or primary drivers of its business. EBITDA, adjusted EBITDA, EBITDA margin and adjusted EBITDA margin provide disclosure on the same basis as that used by Ashland's management to evaluate financial performance on a consolidated and reportable segment basis and provide consistency in our financial reporting, facilitate internal and external comparisons of Ashland's historical operating performance and its business units and provide continuity to investors for comparability purposes. EBITDA margin and adjusted EBITDA margin are defined as EBITDA and adjusted EBITDA divided by sales for the corresponding period.

Key items, which are set forth on Table 7 of this release, are defined as financial effects from significant transactions that, either by their nature or amount, have caused short-term fluctuations in net income and/or operating income which Ashland does not consider to most accurately reflect Ashland's underlying business performance and trends. Further, Ashland believes that providing supplemental information that excludes the financial effects of these items in the financial results will enhance the investor's ability to compare financial performance between reporting periods.

Tax-specific key items, which are set forth on Table 7 of this release, are defined as financial transactions, tax law changes or other matters that fall within the definition of key items as described above. These items relate solely to tax matters and would only be recorded within the income tax caption of the Statement of Consolidated Income. As with all key items, due to their nature, Ashland does not consider the financial effects of these tax-specific key items on net income to be the most accurate reflection of Ashland's underlying business performance and trends.

The free cash flow metric enables Ashland to provide a better indication of the ongoing cash being generated that is ultimately available for both debt and equity holders as well as other investment opportunities. Unlike cash flow provided by operating activities, free cash flow includes the impact of capital expenditures from continuing operations, providing a more complete picture of cash generation. Free cash flow has certain limitations, including that it does not reflect adjustment for certain non-discretionary cash flows such as mandatory debt repayments. The amount of mandatory versus discretionary expenditures can vary significantly between periods.

Adjusted diluted earnings per share is a performance measure used by Ashland and is defined by Ashland as earnings (loss) from continuing operations, adjusted for identified key items and divided by the number of outstanding diluted shares of common stock. Ashland believes this measure provides investors additional insights into operational performance by providing earnings and diluted earnings per share metrics that exclude the effect of the identified key items and tax specific key items.

Adjusted diluted earnings per share, excluding intangibles amortization expense metric enables Ashland to demonstrate the impact of non-cash intangibles amortization expense on earnings per share, in addition to key items previously mentioned. Ashland's management believes this presentation is helpful to illustrate how previous acquisitions impact applicable period results.

About Ashland

Ashland Global Holdings Inc. (NYSE: ASH) is a premier specialty materials company with a conscious and proactive mindset for sustainability. The company serves customers in a wide range of consumer and industrial markets, including adhesives, architectural coatings, automotive, construction, energy, food and beverage, nutraceuticals, personal care and pharmaceutical. Approximately 4,200 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/sustainability to learn more.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as "anticipates," "believes," "expects," "estimates," "is likely," "predicts," "projects," "forecasts," "objectives," "may," "will," "should," "plans" and "intends" and the negative of these words or other comparable terminology. Ashland may from time to time make forward-looking statements in its annual reports, quarterly reports and other filings with the SEC, news releases and other written and oral communications. These forward-looking statements are based on Ashland's expectations and assumptions, as of the date such statements are made, regarding Ashland's future operating performance, financial condition, and expected effects of the COVID-19 pandemic on Ashland's business, as well as the economy and other future events or circumstances. These statements include but may not be limited to Ashland's expectations regarding its ability to drive sales and earnings growth and realize further cost reductions.

Ashland's expectations and assumptions include, without limitation, internal forecasts and analyses of current and future market conditions and trends, management plans and strategies, operating efficiencies and economic conditions (such as prices, supply and demand, cost of raw materials, and the ability to recover raw-material cost increases through price increases), and risks and uncertainties associated with the following: the impact of acquisitions and/or divestitures Ashland has made or may make (including the possibility that Ashland may not realize the anticipated benefits from such transactions); Ashland's substantial indebtedness (including the possibility that such indebtedness and related restrictive covenants may adversely affect Ashland's future cash flows, results of operations, financial condition and its ability to repay debt); severe weather, natural disasters, public-health crises (including the current COVID-19 pandemic), cyber events and legal proceedings and claims (including product recalls, environmental and asbestos matters); the effects of the COVID-19 pandemic on the geographies in which we operate, the end markets we serve and on our supply chain and customers, and without limitation, risks and uncertainties affecting Ashland that are described in Ashland's most recent Form 10-K (including Item 1A Risk Factors) filed with the SEC, which is available on Ashland's website at http://investor.ashland.com or on the SEC's website at http://www.sec.gov. Various risks and uncertainties may cause actual results to differ materially from those stated, projected or implied by any forward-looking statements. The extent and duration of the COVID-19 pandemic on our business and operations is uncertain. Factors that will influence the impact on our business and operations include the duration and extent of the pandemic, the extent of imposed or recommended containment and mitigation measures, and the general economic consequences of the pandemic. Ashland believes its expectations and assumptions ar

¹Financial results are preliminary until Ashland's Form 10-Q is filed with the SEC

TM Trademark, Ashland or its subsidiaries, registered in various countries.

FOR FURTHER INFORMATION:

Investor Relations: Media Relations:
Seth A. Mrozek
+1 (302) 594-5010

Media Relations:
Carolmarie C. Brown
+1 (302) 995-3158

	Three m		
	2020	mber 31	2019
		- —	2019
Sales	\$ 552	*	533
Cost of sales	374		380
GROSS PROFIT	178		153
Selling, general and administrative expense	106		99
Research and development expense	15		16
Intangibles amortization expense	21		21
Equity and other income			
OPERATING INCOME	41		17
Net interest and other expense (income)	(6		10
Net income on divestitures	14	<u> </u>	3
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	61		10
Income tax expense (benefit)		<u> </u>	(24)
INCOME FROM CONTINUING OPERATIONS	61	I	34
Loss from discontinued operations (net of income taxes)	(5	<u> </u>	(2)
NET INCOME	\$ 56	\$	32
			
DILUTED EARNINGS PER SHARE			
Income from continuing operations	\$ 0.99	\$	0.56
Income (loss) from discontinued operations	30.0)	3)	(0.03)
Net income	\$ 0.91	\$	0.53
		-	
AVERAGE DILUTED COMMON SHARES OUTSTANDING	61	ı	61
SALES			
Life Sciences	170		155
Personal Care and Household	126		137
Consumer Specialties	296		292
Specialty Additives	147		139
Performance Adhesives	84		74
Industrial Specialties	231		213
Intermediates & Solvents	33		28
Intersegment Sales			
	<u>\$ 552</u>	<u>\$</u>	533
OPERATING INCOME (LOSS)			
Life Sciences	29)	22
Personal Care and Household	15		11
Consumer Specialties	44		33
Specialty Additives	2		9
Performance Adhesives	20		10
Industrial Specialties	22		19
Intermediates & Solvents	2		(12)
Unallocated and other	(27		(23)
	\$ 41		17
	<u>*</u>	- -	

ASSETS Current assets \$ 335 \$ 454 Accounts receivable 409 471 Inventories 537 529 Other assets 100 87 Held for sale - 6 Total current assets 1,381 1,547 Noncurrent assets **** **** Property, plant and equipment 3,310 3,265 Accumulated depreciation 1,748 1,700 Net property, plant and equipment 1,562 1,565 Goodwill 1,792 1,758 Intangibles 1,001 1,013 Operating lease assets, net 137 137 Restricted investments 316 301 Asbestos insurance receivable 130 136 Deferred income taxes 26 26 Other assets 397 394 Total noncurrent assets \$ 6,742 \$ 6,877		December 20	31 September 30 20 2020
Cash and cash equivalents \$ 335 \$ 454 Accounts receivable 409 471 Inventories 537 529 Other assets 100 87 Held for sale 1,361 1,547 Noncurrent assets - 3 Property, plant and equipment 3,310 3,265 Cost 3,310 3,265 Accurulated depreciation 1,748 1,700 Net property, plant and equipment 1,562 1,565 Goodwill 1,792 1,758 Intangibles 1,001 1,013 Qperating lease assets, net 137 137 Restricted investments 316 301 Asbestos insurance receivable 130 316 Deferred income taxes 26 26 Other assets 397 394 Total ansets 5,361 5,330 Total assets 5,361 5,330 Total assets 5 6,742 5 6,87 LURBILITIES AND EQUITY 2 Current ibabilities 252 227 Trade and other payables 252 227 Total current liabilities 252 228 Noncurrent	ASSETS		<u> </u>
Accounts receivable 409 471 Inventories 537 529 Other assets 100 87 Held for sale 100 87 Total current assets 1,381 1,547 Noncurrent assets \$70 \$70 Property, plant and equipment 3,310 3,265 Cost 3,310 3,265 Accumulated depreciation 1,748 1,700 Net property, plant and equipment 1,562 1,565 Goodwill 1,792 1,565 Intangibles 1,001 1,013 Operating lease assets, net 316 301 Restricted investments 316 301 Asbestos insurance receivable 313 136 Deferred income taxes 26 26 Other assets 397 394 Total assets \$ 6,742 \$ 6,87 LIMBILITIES AND EQUITY \$ 93 \$ 280 Tarde and other payables \$ 93 \$ 280 Trade and other payables			
Inventories			
Other assets 100 87 6 6 6 6 6 7 6 6 7 6 7 1,381 1,547 1,547 1,547 1,547 1,547 1,547 1,547 1,547 1,547 1,547 1,547 1,547 1,548 1,547 1,548 1,702 1,548 1,702 1,558 1,556 3,565 3,561 3,565 3,561 3,565 3,673 3,565 3,673 3,672 3,672 3,672 3,672 3,672 3,672 3,672 3,672 3,672 3,672 3,672 3,672 3,672			
Held for sale	Inventories	5	537 529
Total current assets 1,381 1,547 Noncurrent assets Property, plant and equipment 3,310 3,265 Cost 3,310 3,265 Accumulated depreciation 1,748 1,700 Net property, plant and equipment 1,562 1,565 Godwill 1,792 1,758 Intangibles 1,001 1,013 Operating lease assets, net 137 137 Restricted investments 316 301 Asbestos insurance receivable 130 136 Deferred income taxes 26 26 Other assets 397 394 Total noncurrent assets 5,361 5,330 Total assets \$ 6,742 \$ 6,877 LIABILITIES AND EQUITY 2 2 Current liabilities \$ 217 233 Accrued expenses and other liabilities 217 233 Current operating lease obligations 225 277 Current poperating lease obligations 255 255 Noncurrent liabilities		1	00 87
Noncurrent assets Property, plant and equipment 3,310 3,265 Accumulated depreciation 1,748 1,700 Net property, plant and equipment 1,562 1,565 Goodwill 1,792 1,758 Intangibles 1,001 1,013 Operating lease assets, net 137 137 Restricted investments 316 301 Asbestos insurance receivable 130 136 Deferred income taxes 26 26 Other assets 397 394 Total noncurrent assets 5,361 5,330 Total assets \$ 6,742 \$ 6,877 LIABILITIES AND EQUITY \$ 93 \$ 280 Trade and other payables 217 233 Accrued expenses and other liabilities 25 277 Current operating lease obligations 23 23 Total current liabilities 585 813 Noncurrent liabilities 498 513 Long-term debt 1,601 1,573	Held for sale		
Property, plant and equipment 3,310 3,265 Accumulated depreciation 1,748 1,700 Net property, plant and equipment 1,562 1,565 Goodwill 1,792 1,758 Intangibles 1,001 1,013 Operating lease assets, net 313 137 Restricted investments 316 301 Asbestos insurance receivable 130 136 Deferred income taxes 26 26 Other assets 397 394 Total noncurrent assets 5,361 5,330 Total assets \$ 6,742 \$ 6,877 LIABILITIES AND EQUITY Current liabilities \$ 93 \$ 280 Trade and other payables \$ 93 \$ 280 Trade and other payables \$ 93 \$ 280 Total current liabilities \$ 252 277 Current operating lease obligations \$ 23 23 Total current liabilities \$ 255 813 Noncurrent liabilities \$ 1,601 1,573 </td <td>Total current assets</td> <td>1,3</td> <td>1,547</td>	Total current assets	1,3	1,547
Cost 3,310 3,265 Accumulated depreciation 1,748 1,700 Net property, plant and equipment 1,562 1,565 Goodwill 1,792 1,758 Intangibles 1,001 1,013 Operating lease assets, net 137 137 Restricted investments 316 307 Asbestos insurance receivable 130 136 Deferred income taxes 26 26 Other assets 397 394 Total noncurrent assets 5,361 5,330 Total assets \$ 6,742 6,877 LIABILITIES AND EQUITY 2 2 Current liabilities \$ 93 280 Trade and other payables 217 233 Accrude expenses and other liabilities 252 277 Current operating lease obligations 23 23 Total current liabilities 255 813 Noncurrent liabilities 25 81 Long-term debt 1,601 1,573			
Accumulated depreciation 1,748 1,700 Net property, plant and equipment 1,562 1,565 Goodwill 1,792 1,558 Intangibles 1,001 1,013 Operating lease assets, net 137 137 Restricted investments 316 301 Asbestos insurance receivable 130 133 Deferred income taxes 26 26 Other assets 397 394 Total noncurrent assets 5,361 5,330 Total assets \$ 6,742 \$ 6,877 LIABILITIES AND EQUITY Stockholder payables 29 280 Trade and other payables 217 233 280 Trade and other payables 29 277 20 277 20 277 20 277 20 20 277 20 20 277 20 20 277 20 20 277 20 20 20 20 20 20 20 20 20 20	Property, plant and equipment		
Net property, plant and equipment 1,562 1,565 Goodwill Intangibles Intangible Intang	Cost	3,3	
Goodwill 1,792 1,758 Intangibles 1,001 1,013 Operating lease assets, net 137 137 Restricted investments 316 301 Asbestos insurance receivable 130 136 Deferred income taxes 26 26 Other assets 397 394 Total noncurrent assets 5,361 5,330 Total assets \$ 6,742 \$ 6,872 LABILITIES AND EQUITY *** Current liabilities** Short-term debt \$ 93 \$ 280 Trade and other payables 217 233 Accrued expenses and other liabilities 252 277 Current operating lease obligations 23 23 Total current liabilities 585 813 Noncurrent liabilities 1,601 1,573 Asbestos litigation reserve 498 513 Deferred income taxes 222 229 Employee benefit obligations 157 157 Operating lease obligations 124 124 Other	Accumulated depreciation	1,7	<u>'48</u> <u>1,700</u>
Intangibles 1,001 1,013 Operating lease assets, net 137 137 Restricted investments 316 301 Asbestos insurance receivable 130 136 Deferred income taxes 26 26 Other assets 397 394 Total noncurrent assets 5,361 5,330 Total assets \$6,742 \$6,877 LIABILITIES AND EQUITY \$93 \$280 Current liabilities 217 233 Short-term debt \$93 \$280 Trade and other payables 217 233 Accrued expenses and other liabilities 252 277 Current operating lease obligations 252 27 Total current liabilities 585 813 Noncurrent liabilities 498 513 Deferred income taxes 222 229 Employee benefit obligations 157 157 Operating lease obligations 157 157 Operating lease obligations 124 124	Net property, plant and equipment	1,5	1,565
Operating lease assets, net 137 137 Restricted investments 316 301 Asbestos insurance receivable 130 136 Deferred income taxes 26 26 Other assets 397 394 Total noncurrent assets 5,361 5,330 Total assets \$ 6,742 \$ 6,877 LIABILITIES AND EQUITY Current liabilities Short-term debt \$ 93 \$ 280 Trade and other payables 217 233 Accrued expenses and other liabilities 252 277 Current operating lease obligations 23 23 Total current liabilities 23 23 Noncurrent liabilities 1,601 1,573 Asbestos litigation reserve 498 513 Deferred income taxes 222 229 Employee benefit obligations 157 157 Operating lease obligations 157 157 Operating lease obligations 3,035 3,038 Total nonc	Goodwill	1,7	792 1,758
Restricted investments 316 301 Asbestos insurance receivable 130 136 Deferred income taxes 26 26 Other assets 397 394 Total noncurrent assets 5,361 5,330 Total assets \$ 6,742 \$ 6,877 LIABILITIES AND EQUITY Current liabilities Short-term debt \$ 93 \$ 280 Trade and other payables 217 233 Accrued expenses and other liabilities 252 227 Current operating lease obligations 23 23 Total current liabilities 585 813 Noncurrent liabilities 1,601 1,573 Asbestos litigation reserve 498 513 Deferred income taxes 222 229 Employee benefit obligations 157 157 Operating lease obligations 157 157 Operating lease obligations 3,035 3,038 Total noncurrent liabilities 3,035 3,038	Intangibles	1,0	1,013
Asbestos insurance receivable Deferred income taxes 130 136 Deferred income taxes 26 26 Other assets 397 394 Total noncurrent assets 5,361 5,330 Total assets \$ 6,742 \$ 6,877 LIABILITIES AND EQUITY Current liabilities Short-term debt 93 280 Trade and other payables 217 233 Accrued expenses and other liabilities 252 277 Current operating lease obligations 252 277 Total current liabilities 58 813 Noncurrent liabilities 40 1,601 1,573 Asbestos litigation reserve 498 513 Deferred income taxes 222 229 Employee benefit obligations 157 157 Operating lease obligations 124 124 Other liabilities 433 432 Total noncurrent liabilities 3,035 3,036 Stockholders' equity 3,122 3,036 <td>Operating lease assets, net</td> <td>1</td> <td>37 137</td>	Operating lease assets, net	1	37 137
Deferred income taxes 26 Other assets 26 Other assets 26 Other assets 397 Otal assets 394 Other assets 393 Other assets 5,361 Other assets 6,877 Other assets 5,361 Other assets 6,877 Other assets 5,367 Other assets 5,367 Other assets 5,367 Other assets 6,877 Other assets 5,367 Other assets 5,367 Other assets 6,877 Other assets 5,367 Other assets </td <td>Restricted investments</td> <td>3</td> <td>301</td>	Restricted investments	3	301
Other assets 397 394 Total noncurrent assets 5,361 5,330 Total assets \$ 6,742 6,877 LIABILITIES AND EQUITY Current liabilities Short-term debt \$ 93 280 Trade and other payables 217 233 Accrued expenses and other liabilities 252 277 Current operating lease obligations 23 23 Total current liabilities 585 813 Noncurrent liabilities 1,601 1,573 Asbestos litigation reserve 498 513 Deferred income taxes 222 229 Employee benefit obligations 157 157 Operating lease obligations 124 124 Other liabilities 433 432 Total noncurrent liabilities 3,035 3,036 Stockholders' equity 3,122 3,036	Asbestos insurance receivable	1	30 136
Total noncurrent assets 5,361 5,330 Total assets \$ 6,742 \$ 6,877 LIABILITIES AND EQUITY Current liabilities Short-term debt \$ 93 \$ 280 Trade and other payables 217 233 Accrued expenses and other liabilities 252 277 Current operating lease obligations 23 23 Total current liabilities 585 813 Noncurrent liabilities 1,601 1,573 Asbestos litigation reserve 498 513 Deferred income taxes 222 229 Employee benefit obligations 157 157 Operating lease obligations 124 124 Other liabilities 433 432 Total noncurrent liabilities 3,035 3,036 Stockholders' equity 3,036	Deferred income taxes		26 26
Total assets \$ 6,742 \$ 6,877 LIABILITIES AND EQUITY Current liabilities Short-term debt \$ 93 \$ 280 Trade and other payables 217 233 Accrued expenses and other liabilities 252 277 Current operating lease obligations 23 23 Total current liabilities \$ 585 813 Noncurrent liabilities 1,601 1,573 Asbestos litigation reserve 498 513 Deferred income taxes 222 229 Employee benefit obligations 157 157 Operating lease obligations 157 157 Operating lease obligations 124 124 Other liabilities 3,035 3,028 Stockholders' equity 3,122 3,036	Other assets	3	394
LIABILITIES AND EQUITY Current liabilities \$ 93 \$ 280 Short-term debt 217 233 Accrued expenses and other liabilities 252 277 Current operating lease obligations 23 23 Total current liabilities 585 813 Noncurrent liabilities \$ 1,601 1,573 Asbestos litigation reserve 498 513 Deferred income taxes 222 229 Employee benefit obligations 157 157 Operating lease obligations 124 124 Other liabilities 3,035 3,028 Stockholders' equity 3,122 3,036	Total noncurrent assets	5,3	5,330
Current liabilities Short-term debt \$ 93 \$ 280 Trade and other payables 217 233 Accrued expenses and other liabilities 252 277 Current operating lease obligations 23 23 Total current liabilities 585 813 Noncurrent liabilities \$ 1,601 1,573 Asbestos litigation reserve 498 513 Deferred income taxes 222 229 Employee benefit obligations 157 157 Operating lease obligations 157 157 Other liabilities 433 432 Total noncurrent liabilities 3,035 3,028 Stockholders' equity 3,122 3,036	Total assets	\$ 6,7	42 \$ 6,877
Short-term debt \$ 93 280 Trade and other payables 217 233 Accrued expenses and other liabilities 252 277 Current operating lease obligations 23 23 Total current liabilities 585 813 Noncurrent liabilities 585 813 Long-term debt 1,601 1,573 Asbestos litigation reserve 498 513 Deferred income taxes 222 229 Employee benefit obligations 157 157 Operating lease obligations 124 124 Other liabilities 433 432 Total noncurrent liabilities 3,035 3,028 Stockholders' equity 3,122 3,036	LIABILITIES AND EQUITY		
Trade and other payables 217 233 Accrued expenses and other liabilities 252 277 Current operating lease obligations 23 23 Total current liabilities 585 813 Noncurrent liabilities 585 813 Long-term debt 1,601 1,573 Asbestos litigation reserve 498 513 Deferred income taxes 222 229 Employee benefit obligations 157 157 Operating lease obligations 124 124 Other liabilities 433 432 Total noncurrent liabilities 3,035 3,028 Stockholders' equity 3,122 3,036	Current liabilities		
Trade and other payables 217 233 Accrued expenses and other liabilities 252 277 Current operating lease obligations 23 23 Total current liabilities 585 813 Noncurrent liabilities 585 813 Long-term debt 1,601 1,573 Asbestos litigation reserve 498 513 Deferred income taxes 222 229 Employee benefit obligations 157 157 Operating lease obligations 124 124 Other liabilities 433 432 Total noncurrent liabilities 3,035 3,028 Stockholders' equity 3,122 3,036	Short-term debt	\$	93 \$ 280
Accrued expenses and other liabilities 252 277 Current operating lease obligations 23 23 Total current liabilities 585 813 Noncurrent liabilities 1,601 1,573 Long-term debt 1,601 1,573 Asbestos litigation reserve 498 513 Deferred income taxes 222 229 Employee benefit obligations 157 157 Operating lease obligations 124 124 Other liabilities 433 432 Total noncurrent liabilities 3,035 3,028 Stockholders' equity 3,122 3,036	Trade and other payables		217 233
Current operating lease obligations 23 23 Total current liabilities 585 813 Noncurrent liabilities 1,601 1,573 Long-term debt 498 513 Deferred income taxes 222 229 Employee benefit obligations 157 157 Operating lease obligations 124 124 Other liabilities 433 432 Total noncurrent liabilities 3,035 3,028 Stockholders' equity 3,122 3,036		2	252 277
Total current liabilities 585 813 Noncurrent liabilities 1,601 1,573 Long-term debt 1,601 1,573 Asbestos litigation reserve 498 513 Deferred income taxes 222 229 Employee benefit obligations 157 157 Operating lease obligations 124 124 Other liabilities 433 432 Total noncurrent liabilities 3,035 3,028 Stockholders' equity 3,122 3,036			23 23
Long-term debt 1,601 1,573 Asbestos litigation reserve 498 513 Deferred income taxes 222 229 Employee benefit obligations 157 157 Operating lease obligations 124 124 Other liabilities 433 432 Total noncurrent liabilities 3,035 3,028 Stockholders' equity 3,122 3,036	Total current liabilities		813
Asbestos litigation reserve 498 513 Deferred income taxes 222 229 Employee benefit obligations 157 157 Operating lease obligations 124 124 Other liabilities 433 432 Total noncurrent liabilities 3,035 3,028 Stockholders' equity 3,122 3,036	Noncurrent liabilities		
Deferred income taxes 222 229 Employee benefit obligations 157 157 Operating lease obligations 124 124 Other liabilities 433 432 Total noncurrent liabilities 3,035 3,028 Stockholders' equity 3,122 3,036	Long-term debt	1,6	501 1,573
Employee benefit obligations 157 157 Operating lease obligations 124 124 Other liabilities 433 432 Total noncurrent liabilities 3,035 3,028 Stockholders' equity 3,122 3,036	Asbestos litigation reserve	4	.98 513
Operating lease obligations 124 124 Other liabilities 433 432 Total noncurrent liabilities 3,035 3,028 Stockholders' equity 3,122 3,036		2	222 229
Operating lease obligations 124 124 Other liabilities 433 432 Total noncurrent liabilities 3,035 3,028 Stockholders' equity 3,122 3,036	Employee benefit obligations	1	57 157
Other liabilities433432Total noncurrent liabilities3,0353,028Stockholders' equity3,1223,036			
Total noncurrent liabilities 3,035 3,028 Stockholders' equity 3,122 3,036			
	Total noncurrent liabilities		
Total liabilities and stockholders' equity \$ 6,742 \$ 6,877	Stockholders' equity	3,1	22 3,036
	Total liabilities and stockholders' equity	\$ 6,7	42 \$ 6,877

Three months ended

	1111	December 31		
	2020	Decem	Del 31	2019
CASH FLOWS PROVIDED (USED) BY OPERATING ACTIVITIES		—		
FROM CONTINUING OPERATIONS				
Net income (loss)	\$	56	\$	32
Loss from discontinued operations (net of taxes)	·	5	•	2
Adjustments to reconcile income from continuing operations to				
cash flows from operating activities				
Depreciation and amortization		62		61
Original issue discount and debt issuance cost amortization		1		2
Deferred income taxes		(5)		(12)
Gain from sales of property and equipment		(4)		-
Stock based compensation expense		4		4
Income from restricted investments		(23)		(13)
Net income on divestitures		(14)		-
Impairments		9		-
Pension contributions		(2)		(1)
Change in operating assets and liabilities (a)		17		(109)
Total cash flows provided (used) by operating activities from continuing operations		106		(34)
CASH FLOWS PROVIDED (USED) BY INVESTING ACTIVITIES				
FROM CONTINUING OPERATIONS				
Additions to property, plant and equipment		(30)		(29)
Proceeds from disposal of property, plant and equipment		5		-
Proceeds from sale or restructuring of operations		14		-
Net purchase of funds restricted for specific transactions		(1)		(1)
Reimbursements from restricted investments		8		10
Proceeds from sale of securities		42		4
Purchases of securities		(42)		(4)
Total cash flows used by investing activities from continuing operations		(4)		(20)
CASH FLOWS PROVIDED (USED) BY FINANCING ACTIVITIES				
FROM CONTINUING OPERATIONS				
Proceeds from (repayment of) short-term debt		(187)		14
Cash dividends paid		(17)		(16)
Stock based compensation employee withholding taxes paid in cash		(3)		(5)
Total cash flows used by financing activities from continuing operations		(207)		<u>(7</u>)
CASH PROVIDED (USED) BY CONTINUING OPERATIONS		(105)		(61)
Cash provided (used) by discontinued operations				
Operating cash flows		(14)		(17)
Investing cash flows		(3)		2
Effect of currency exchange rate changes on cash and cash equivalents		3		1
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		(119 ₎		<u>(75</u>)
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD		454		232
CASH AND CASH EQUIVALENTS - END OF PERIOD	<u>\$</u>	335	\$	157
DEPRECIATION AND AMORTIZATION				
Life Sciences		16		15
Personal Care and Household		19		19
Consumer Specialties		35		34
Specialty Additives		21		20
Performance Adhesives		3		4
Industrial Specialties		24		24
Intermediates & Solvents		3		3
Unallocated and other				<u> </u>
	\$	62	\$	61
(a) Fold the decrease West from a conflict on the field conflict.				

Excludes changes resulting from operations acquired or sold.

			onths ended ember 31		
Adjusted EBITDA - Ashland Global Holdings Inc.		2020	2	2019	
Net income	\$	56	\$	32	
Income tax expense (benefit)		-		(24)	
Net interest and other expense (income)		(6)		10	
Depreciation and amortization		62		61	
EBITDA		112		79	
Loss from discontinued operations (net of taxes)		5		2	
Net income on divestitures key items (see Table 5)		(14)		-	
Operating key items (see Table 5)		21		7	
Adjusted EBITDA	\$	124	\$	88	
Life Sciences					
Operating income	\$	29	\$	22	
Add:					
Depreciation and amortization		16		15	
Adjusted EBITDA	\$	45	\$	37	
			-		
Personal Care and Household					
Operating income	\$	15	\$	11	
Add:					
Depreciation and amortization		19		19	
Adjusted EBITDA	<u>\$</u>	34	\$	30	
Adjusted EBITDA - Consumer Specialties Total					
Operating income		44	\$	33	
Add:					
Depreciation and amortization		35		34	
Adjusted EBITDA	\$	79	\$	67	
•	<u></u>		<u> </u>		

		onths ende mber 31	ed
	2020	201	19
Specialty Additives			
Operating income	2	\$	9
Add:			
Depreciation and amortization	21		20
Operating key items (see Table 5)	9		
Adjusted EBITDA	32	\$	29
Performance Adhesives			
Operating income	20	\$	10
Add:			
Depreciation and amortization	3		4
Adjusted EBITDA	23	\$	14
Adjusted EBITDA - Industrial Specialties Total			
Operating income	5 22	\$	19
Add:			
Depreciation and amortization	24		24
Operating key items (see Table 5)	9		
Adjusted EBITDA	55	\$	43
Adjusted EBITDA - Intermediates and Solvents			
Operating income \$	2	\$	(12)
Add:			
Depreciation and amortization	3 5 5		3
Adjusted EBITDA	5 5	\$	(9)

Ashland Global Holdings Inc. and Consolidated Subsidiaries SEGMENT COMPONENTS OF KEY ITEMS FOR APPLICABLE INCOME STATEMENT **CAPTIONS**

(In millions - preliminary and unaudited)

						Thre	ee Mon	ths End	ded Dece	ember 3	31, 2020						
	Life Sciences		Personal Care and ousehold	Cons	umer	Spec Addit	ialty	Perfor	rmance esives	Indu: Speci	strial	Intern	nediates Solvents		ocated Other	т	otal
OPERATING INCOME (LOSS) Operating key items:	Colonoco	<u></u>	<u>odocrioid</u>	Орос	<u>untioo</u>	7 tadit		710110	301700	Орос	<u>untioo</u>	<u>una c</u>	JOI VOIILO		-		7(4)
Restructuring, separation and other costs Capital project impairment	\$ -	\$	-	\$	-	\$	(9)	\$	-	\$	(9)	\$	-	\$	(12)	\$	(12) (9)
All other operating income (loss) Operating income (loss)	<u>29</u> 29	_	15 15		44		<u>11</u> 2		20		31 22		2		(15) (27)		62 41
NET INTEREST AND OTHER EXPENSE (INCOME) Key items All other net interest and other expense (income)															(18) 12 (6)		(18) 12 (6)
NET INCOME ON DIVESTITURES Key items															14		14
INCOME TAX EXPENSE (BENEFIT) Tax effect of key items (a) Tax specific key items (b) All other income tax expense (benefit)															4 (13) 9		4 (13) 9
INCOME (LOSS) FROM CONTINUING OPERATIONS	\$ 29	\$	15	\$	44	\$	2	\$	20	\$	22	\$	2	\$	(7)	\$	61
						Thr	ee Mon	ths En	ded Dec	ember 3	31, 2019)					
	Life Sciences		Personal Care and ousehold		sumer ialties	Spec Addit			rmance esives	Indu	strial ialties		nediates Solvents		ocated other	т	otal
OPERATING INCOME (LOSS) Operating key items:	<u> </u>	- <u></u>	ouseriola	Spec	iaities	Addit	iives_	Auti	esives	эрес	iaities	anu c	olvents	_ a c	tilei		Jiai
Restructuring, separation and other costs All other operating income (loss) Operating income (loss)	\$ 22 22	\$ 	11 11	\$	33 33	\$	9	\$	10 10	\$	19 19	\$	(12) (12)	\$	(7) (16) (23)	\$	(7) 24 17
NET INTEREST AND OTHER EXPENSE (INCOME) Key items All other net interest and other expense (income)															(9) 19 10		(9) 19 10
NET INCOME ON DIVESTITURES															3		3
INCOME TAX EXPENSE (BENEFIT) Tax effect of key items (a) Tax specific key items (b) All other income tax expense (benefit)															1 (25) - (24)		1 (25) - (24)
INCOME (LOSS) FROM CONTINUING OPERATIONS	\$ 22	\$	11	\$	33	\$	9	\$	10	\$	19	\$	(12)	\$	(6)	\$	34

⁽a) Represents the tax effect of the key items that are previously identified above.

Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. See Table 7 for additional information. (b)

	Three months ended December 31								
Free cash flows (a)	20	020	2	019					
Total cash flows provided by operating activities from continuing operations	\$	106	\$	(34)					
Adjustments: Additions to property, plant and equipment		(30)		(29)					
Free cash flows (a) (b)	\$	76	\$	(63)					

- Free cash flow is defined as cash flows provided (used) by operating activities less additions to property, plant and equipment and other items Ashland has deemed non-operational (if (a) applicable).

 Includes \$14 million and \$6 million of restructuring payments for the three months ended December 31, 2020 and 2019, respectively.
- (b)

	Three months ende December 31							
Adjusted operating income	2020		2019					
Operating income (as reported)	\$ 4	1 \$	17					
Key items, before tax:								
Restructuring, separation and other costs	1	2	7					
Capital project impairment		9	-					
Adjusted operating income (non-GAAP)	\$ 6	<u>\$</u>	24					

(In millions except per share data - preliminary and unaudited)

17

17

58

RECONCILIATION OF CERTAIN NON-GAAP DATA

Amortization expense adjustment (net of tax) (c)

Three months ended December 31 2020 2019 Income from continuing operations (as reported) 61 34 Key items, before tax: Restructuring, separation and other costs 7 12 Capital project impairment 9 Unrealized gain on securities (9) (18)Net gain on acquisitions and divestitures (14) Key items, before tax (11)(2) Tax effect of key items (a) Key items, after tax (7) (1) Tax specific key items: Restructuring and separation activity (13)Other tax reform related activity (25)Tax specific key items (b) (13) (25)Total key items (20)(26)Adjusted income from continuing operations (non-GAAP) 41 8

Represents the tax effect of the key items that are previously identified above. (a)

Adjusted income from continuing operations (non-GAAP) excluding intangibles amortization expense

- (b) Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. These tax specific key items
 - Restructuring and separation activity: Includes the impact from company-wide restructuring activities. These adjustments related to various tax impacts including state tax costs, foreign tax costs and other tax account adjustments.

 Other tax reform: Includes the impact of other items related to the Tax Act and other tax law changes enacted during 2020.
- (c) Amortization expense adjustment (net of tax) tax rates were 21% and 20% for the three months ended December 31, 2020 and 2019, respectively.

Three months ended

(In millions except per share data - preliminary and unaudited)

	December 31			
	20	20		2019
Diluted EPS from continuing operations (as reported)	\$	0.99	\$	0.56
Key items, before tax:				
Restructuring, separation and other costs		0.18		0.12
Capital project impairment		0.16		-
Unrealized gain on securities		(0.29)		(0.15)
Net gain on acquisitions and divestitures		(0.23)		
Key items, before tax		(0.18)		(0.03)
Tax effect of key items (a)		0.07		0.02
Key items, after tax		(0.11)		(0.01)
Tax specific key items:				
Restructuring and separation activity		(0.22)		-
Other tax reform related activity				(0.42)
Tax specific key items (b)	· ·	(0.22)		(0.42)
Total key items		(0.33)		(0.43)
Adjusted diluted EPS from continuing operations (non-GAAP)	\$	0.66	\$	0.13
Amortization expense adjustment (net of tax) (c)		0.28		0.28
Adjusted diluted EPS from continuing operations (non-GAAP) excluding intangibles amortization expense	\$	0.94	\$	0.41

- (a) Represents the tax effect of the key items that are previously identified above.
- Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. These tax specific key items included the following:

 Restructuring and separation activity: Includes the impact from company-wide restructuring activities. These adjustments related to various tax impacts including state tax costs, foreign tax costs and other tax account adjustments.

 Other tax reform: Includes the impact of other items related to the Tax Act and other tax law changes enacted during 2020. (b)
- Amortization expense adjustment (net of tax) tax rates were 21% and 20% for the three months ended December 31, 2020 and 2019, respectively. (c)